The University of Texas MD Anderson Cancer Center

Medicine & Life Sciences

1. Neoplasms 100%
2. Breast Neoplasms 47%
3. Survival 43%
4. Therapeutics 37%
5. Neoplasm Metastasis 32%
6. Radiotherapy 32%
7. Genes 30%
8. Drug Therapy 29%
9. Proteins 21%
10. Mutation 21%
11. Carcinoma 21%
12. Apoptosis 20%
13. Recurrence 19%
14. Prostatic Neoplasms 19%
15. Colorectal Neoplasms 19%
16. Melanoma 18%
17. Non-Small Cell Lung Carcinoma 18%
18. Growth 17%
19. Cell Line 16%
20. Lung Neoplasms 16%
21. DNA 16%
22. T-Lymphocytes 15%
23. Radiation 15%
24. Hepatocellular Carcinoma 14%
25. Adenocarcinoma 14%
26. Nasopharyngeal Carcinoma 14%
27. Acute Myeloid Leukemia 14%
28. Pancreatic Neoplasms 13%
29. Liver 13%
30. Population 13%
31. Confidence Intervals 13%
32. Ovarian Neoplasms 13%
33. Biomarkers 13%
34. Lymph Nodes 12%
35. Breast 12%
36. Lung 12%
37. In Vitro Techniques 12%
38. Leukemia 12%
39. Glioma 12%
40. Stomach Neoplasms 11%
41. Carcinogenesis 11%
42. Squamous Cell Carcinoma 11%
43. Gene Expression 11%
44. Progression-Free Survival 11%
45. Incidence 10%
46. MicroRNAs 10%
47. Glioblastoma 10%
48. Lymphoma 9%
49. Clinical Trials 9%
50. ErbB Receptors 9%
51. Cisplatin 9%
52. Bone Marrow 9%
53. Pharmaceutical Preparations 9%
54. Messenger RNA 9%
55. Immunotherapy 9%
56. Stem Cells 9%
57. Renal Cell Carcinoma 9%
58. Skin 8%
59. Mortality 8%
60. Uterine Cervical Neoplasms 8%
61. Safety 8%
62. Sarcoma 8%
63. Phenotype 8%
64. Serum 8%
65. B-Cell Chronic Lymphocytic Leukemia 8%
66. Survival Rate 8%
67. Phosphotransferases 8%
68. Genome 8%
69. Odds Ratio 8%
70. Biopsy 7%
71. Down-Regulation 7%
72. Methylation 7%
73. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7%
74. Head and Neck Neoplasms 7%
75. Phosphorylation 7%
76. Heterografts 7%
77. Brain 7%
78. Multiple Myeloma 7%
79. Cell Proliferation 7%
80. Precursor Cell Lymphoblastic Leukemia-Lymphoma 7%
81. Tomography 7%
82. Ligands 7%
83. Urinary Bladder Neoplasms 7%
84. Protein-Tyrosine Kinases 7%
85. Cancer Survivors 7%
86. Prostate 7%
87. Transplants 7%
88. Single Nucleotide Polymorphism 7%
89. Guidelines 7%
90. Genotype 6%
91. Colonic Neoplasms 6%
92. Chromosomes 6%
93. Doxorubicin 6%
94. Antibodies 6%
95. Magnetic Resonance Imaging 6%
96. DNA Damage 6%
97. Kidney 6%
98. Quality of Life 6%
99. Chemoradiotherapy 6%
100. B-Lymphocytes 6%